AMAR

Amarillo Biosciences, Inc. is a biopharmaceutical company specializing in the development of low-dose oral interferon alpha for the treatment of autoimmune and infectious diseases. The company's lead product candidate, Veldona, has been extensively evaluated in clinical trials for Sjögren's syndrome and has demonstrated potential in treating viral infections such as Hepatitis C and influenza. Amarillo Biosciences focuses on providing non-invasive, cost-effective therapeutic alternatives to traditional injectable interferon treatments. In recent years, the company has diversified its business model through strategic acquisitions in the medical technology and consumer health sectors. The firm continues to leverage its expertise in interferon-based immunology to address emerging global health challenges, including COVID-19.